Sanford Bart Ben
Known title: EVP, OperationsCIK: 0001751365
Associated companies
Transaction History
| INGN | ▼ Sell | Tax Withholding | 507 | $8K | 3/1/2023 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 1,166 | $18K | 3/1/2023 | View on chart |
| INGN | ▲ Buy | Option Exercise | 2,402 | $0 | 3/1/2023 | View on chart |
| INGN | ▲ Buy | Grant | 1,135 | $0 | 3/1/2023 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 318 | $7K | 12/1/2022 | View on chart |
| INGN | ▲ Buy | Option Exercise | 508 | $0 | 12/1/2022 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 318 | $9K | 9/1/2022 | View on chart |
| INGN | ▲ Buy | Option Exercise | 508 | $0 | 9/1/2022 | View on chart |
| INGN | ▲ Buy | Option Exercise | 508 | $0 | 6/1/2022 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 318 | $8K | 6/1/2022 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 675 | $24K | 3/1/2022 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 737 | $26K | 3/1/2022 | View on chart |
| INGN | ▲ Buy | Option Exercise | 1,214 | $0 | 3/1/2022 | View on chart |
| INGN | ▲ Buy | Grant | 1,635 | $0 | 3/1/2022 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 644 | $23K | 3/1/2022 | View on chart |
| INGN | ▲ Buy | Grant | 2,184 | $0 | 3/1/2022 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 911 | $32K | 3/1/2022 | View on chart |
| INGN | ▲ Buy | Grant | 1,881 | $0 | 3/1/2022 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 225 | $7K | 12/1/2021 | View on chart |
| INGN | ▲ Buy | Option Exercise | 273 | $0 | 12/1/2021 | View on chart |
| INGN | ▲ Buy | Option Exercise | 273 | $0 | 9/1/2021 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 225 | $14K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Medical device growth debate touches Inogen sector
A recent Yahoo article examined whether ResMed or Stryker offers a better path to capture medical device growth. Inogen operates in the same medical device market, so the analysis is relevant to how the sector is being evaluated. The discussion may influence how market participants view companies that provide portable oxygen solutions.
Medical device growth debate touches Inogen sector. A recent Yahoo article examined whether ResMed or Stryker offers a better path to capture medical device growth. Inogen operates in the same medical device market, so the analysis is relevant to how the sector is being evaluated. The discussion may influence how market participants view companies that provide portable oxygen solutions.